Fujirebio Europe N.V. Obtains CE Mark for in Vitro Diagnostic Medical Device to Measure pTau217 in Blood for Alzheimer's Disease Pathological Changes in Europe
NQ Score
86/100
N1 Content Completeness
85
AI Summary (NQ-processed)
Fujirebio Europe N.V., a subsidiary of Fujirebio Holdings Inc., has received CE Marking in Europe for its in vitro diagnostic reagent that measures pTau217 in plasma, used with the LUMIPULSE® G1200 and LUMIPULSE® G600II automated chemiluminescent enzyme immunoassay systems, aiding in the diagnosis of Alzheimer's disease in patients aged 50 and older.